Skip to main content
Top
Published in: Journal of Gastrointestinal Surgery 2/2017

01-02-2017 | Review Article

Surgical Considerations in the Treatment of Small Bowel Crohn’s Disease

Authors: Lillias Holmes Maguire, Karim Alavi, Ranjan Sudan, Paul E. Wise, Andreas M. Kaiser, Liliana Bordeianou

Published in: Journal of Gastrointestinal Surgery | Issue 2/2017

Login to get access

Abstract

Surgery remains a cornerstone of the management of Crohn’s disease (CD). Despite the rise of biologic therapy, most CD patients require surgery for penetrating, obstructing, or malignant complications. Optimal surgical therapy requires sophisticated operative judgment and medical optimization. Intraoperatively, surgeons must balance treatment of CD complications against bowel preservation and functional outcome. This demands mastery of multiple techniques for anastomosis and strictureplasty, accurate assessment of bowel integrity for margin minimization, and a comprehensive skillset for navigating adhesions and altered anatomy, controlling thickened mesentery, and safely managing the hostile abdomen. Outside of the operating room, a multi-disciplinary team is critical for pre-operative optimization, patient support, and medical management. Postoperatively, prevention and surveillance of recurrence remain a matter of research and debate, and medical options include older drugs with limited efficacy and tolerability versus biologic agents with greater effect sizes and shorter track records. The evidence base for current management is limited by the inherent challenges of studying a chronic disease marked by heterogeneity and recurrence, but also by a lack of prospective trials incorporating both medical and surgical therapies.
Literature
1.
go back to reference Bernell O, Lapidus A, Hellers G. Risk factors for surgery and recurrence in 907 patients with primary ileocaecal Crohn’s disease. Br J Surg. 2000;87(12):1697–1701.CrossRefPubMed Bernell O, Lapidus A, Hellers G. Risk factors for surgery and recurrence in 907 patients with primary ileocaecal Crohn’s disease. Br J Surg. 2000;87(12):1697–1701.CrossRefPubMed
2.
go back to reference Sjöberg D, Holmström T, Larsson M, et al. Incidence and clinical course of Crohn’s disease during the first year—Results from the IBD cohort of the Uppsala region (ICURE) of Sweden 2005–2009. Journal of Crohn’s and Colitis. 2014;8(3):215–222.CrossRefPubMed Sjöberg D, Holmström T, Larsson M, et al. Incidence and clinical course of Crohn’s disease during the first year—Results from the IBD cohort of the Uppsala region (ICURE) of Sweden 2005–2009. Journal of Crohn’s and Colitis. 2014;8(3):215–222.CrossRefPubMed
3.
go back to reference Frolkis AD, Lipton DS, Fiest KM, et al. Cumulative incidence of second intestinal resection in Crohn’s disease: A systematic review and meta-analysis of population-based studies. Am J Gastroenterol. 2014;109(11):1739–1748.CrossRefPubMed Frolkis AD, Lipton DS, Fiest KM, et al. Cumulative incidence of second intestinal resection in Crohn’s disease: A systematic review and meta-analysis of population-based studies. Am J Gastroenterol. 2014;109(11):1739–1748.CrossRefPubMed
4.
go back to reference Watanabe K, Sasaki I, Fukushima K, et al. Long-term incidence and characteristics of intestinal failure in Crohn’s disease: A multicenter study. J Gastroenterol. 2013:1–8. Watanabe K, Sasaki I, Fukushima K, et al. Long-term incidence and characteristics of intestinal failure in Crohn’s disease: A multicenter study. J Gastroenterol. 2013:1–8.
5.
go back to reference He X, Lin X, Lian L, et al. Preoperative percutaneous drainage of spontaneous intra-abdominal abscess in patients with Crohn’s disease: A meta-analysis. J Clin Gastroenterol. 2014. He X, Lin X, Lian L, et al. Preoperative percutaneous drainage of spontaneous intra-abdominal abscess in patients with Crohn’s disease: A meta-analysis. J Clin Gastroenterol. 2014.
6.
go back to reference Ananthakrishnan AN, McGinley EL. Treatment of intra-abdominal abscesses in Crohn’s disease: A nationwide analysis of patterns and outcomes of care. Dig Dis Sci. 2013;58(7). Ananthakrishnan AN, McGinley EL. Treatment of intra-abdominal abscesses in Crohn’s disease: A nationwide analysis of patterns and outcomes of care. Dig Dis Sci. 2013;58(7).
7.
go back to reference Bellolio F, Cohen Z, Macrae H, et al. Outcomes following surgery for perforating Crohn’s disease. Br J Surg. 2013;100(10):1344–1348.CrossRefPubMed Bellolio F, Cohen Z, Macrae H, et al. Outcomes following surgery for perforating Crohn’s disease. Br J Surg. 2013;100(10):1344–1348.CrossRefPubMed
8.
go back to reference Eshuis EJ, Bemelman WA, van Bodegraven AA, et al. Laparoscopic ileocolic resection versus infliximab treatment of distal ileitis in Crohn’s disease: A randomized multicenter trial (LIR! C-trial). BMC surgery. 2008;8(1):15.CrossRefPubMedPubMedCentral Eshuis EJ, Bemelman WA, van Bodegraven AA, et al. Laparoscopic ileocolic resection versus infliximab treatment of distal ileitis in Crohn’s disease: A randomized multicenter trial (LIR! C-trial). BMC surgery. 2008;8(1):15.CrossRefPubMedPubMedCentral
9.
go back to reference Waterland P, Athanasiou T, Patel H. Post-operative abdominal complications in Crohn’s disease in the biological era: Systematic review and meta-analysis. World J Gastrointest Surg. 2016;8(3):274–83.CrossRefPubMedPubMedCentral Waterland P, Athanasiou T, Patel H. Post-operative abdominal complications in Crohn’s disease in the biological era: Systematic review and meta-analysis. World J Gastrointest Surg. 2016;8(3):274–83.CrossRefPubMedPubMedCentral
10.
go back to reference Appau KA, Fazio VW, Shen B, Church JM, Lashner B, Remzi F, Brzezinski A, Strong SA, Hammel J, Kiran RP. Use of infliximab within 3 months of ileocolonic resection is associated with adverse postoperative outcomes in Crohn’s patients. Gastrointest Surg. 2008;12(10):1738–44.CrossRef Appau KA, Fazio VW, Shen B, Church JM, Lashner B, Remzi F, Brzezinski A, Strong SA, Hammel J, Kiran RP. Use of infliximab within 3 months of ileocolonic resection is associated with adverse postoperative outcomes in Crohn’s patients. Gastrointest Surg. 2008;12(10):1738–44.CrossRef
11.
go back to reference Canedo J, Lee SH, Pinto R, Murad-Regadas S, Rosen L, Wexner SD. Surgical resection in Crohn’s disease: is immunosuppressive medication associated with higher postoperative infection rates? Colorectal Dis. 2011;13(11):1294–8.CrossRefPubMed Canedo J, Lee SH, Pinto R, Murad-Regadas S, Rosen L, Wexner SD. Surgical resection in Crohn’s disease: is immunosuppressive medication associated with higher postoperative infection rates? Colorectal Dis. 2011;13(11):1294–8.CrossRefPubMed
12.
go back to reference Colombel JF, Loftus EV Jr, Tremaine WJ, Pemberton JH, Wolff BG, Young-Fadok T, Harmsen WS, Schleck CD, Sandborn WJ. Early postoperative complications are not increased in patients with Crohn’s disease treated perioperatively with infliximab or immunosuppressive therapy. Am J Gastroenterol. 2004;99(5):878–83CrossRefPubMed Colombel JF, Loftus EV Jr, Tremaine WJ, Pemberton JH, Wolff BG, Young-Fadok T, Harmsen WS, Schleck CD, Sandborn WJ. Early postoperative complications are not increased in patients with Crohn’s disease treated perioperatively with infliximab or immunosuppressive therapy. Am J Gastroenterol. 2004;99(5):878–83CrossRefPubMed
13.
go back to reference El-Hussuna A, Andersen J, Bisgaard T, Jess P, Henriksen M, Oehlenschlager J, Thorlacius-Ussing O, Olaison G. Biologic treatment or immunomodulation is not associated with postoperative anastomotic complications in abdominal surgery for Crohn’s disease. Scand J Gastroenterol. 2012;47(6):662–8.CrossRefPubMed El-Hussuna A, Andersen J, Bisgaard T, Jess P, Henriksen M, Oehlenschlager J, Thorlacius-Ussing O, Olaison G. Biologic treatment or immunomodulation is not associated with postoperative anastomotic complications in abdominal surgery for Crohn’s disease. Scand J Gastroenterol. 2012;47(6):662–8.CrossRefPubMed
14.
go back to reference Kasparek MS, Bruckmeier A, Beigel F, Müller MH, Brand S, Mansmann U, Jauch KW, Ochsenkühn T, Kreis ME. Infliximab does not affect postoperative complication rates in Crohn’s patients undergoing abdominal surgery. Inflamm Bowel Dis. 2012;18(7):1207–13.CrossRefPubMed Kasparek MS, Bruckmeier A, Beigel F, Müller MH, Brand S, Mansmann U, Jauch KW, Ochsenkühn T, Kreis ME. Infliximab does not affect postoperative complication rates in Crohn’s patients undergoing abdominal surgery. Inflamm Bowel Dis. 2012;18(7):1207–13.CrossRefPubMed
15.
go back to reference Myrelid P, Marti-Gallostra M, Ashraf S, Sunde ML, Tholin M, Oresland T, Lovegrove RE, Tøttrup A, Kjaer DW, George BD. Complications in surgery for Crohn’s disease after preoperative antitumour necrosis factor therapy. Br J Surg. 2014;101(5):539–45.CrossRefPubMed Myrelid P, Marti-Gallostra M, Ashraf S, Sunde ML, Tholin M, Oresland T, Lovegrove RE, Tøttrup A, Kjaer DW, George BD. Complications in surgery for Crohn’s disease after preoperative antitumour necrosis factor therapy. Br J Surg. 2014;101(5):539–45.CrossRefPubMed
16.
go back to reference Nasir BS, Dozois EJ, Cima RR, Pemberton JH, Wolff BG, Sandborn WJ, Loftus EV, Larson DW. Perioperative anti-tumor necrosis factor therapy does not increase the rate of early postoperative complications in Crohn’s disease. J Gastrointest Surg. 2010;14(12):1859–65.CrossRefPubMed Nasir BS, Dozois EJ, Cima RR, Pemberton JH, Wolff BG, Sandborn WJ, Loftus EV, Larson DW. Perioperative anti-tumor necrosis factor therapy does not increase the rate of early postoperative complications in Crohn’s disease. J Gastrointest Surg. 2010;14(12):1859–65.CrossRefPubMed
17.
go back to reference Nørgård BM, Nielsen J, Qvist N, Gradel KO, de Muckadell OB, Kjeldsen J. Pre-operative use of anti-TNF-α agents and the risk of post-operative complications in patients with Crohn’s disease—a nationwide cohort study. Aliment Pharmacol Ther. 2013;37(2):214–24.CrossRefPubMed Nørgård BM, Nielsen J, Qvist N, Gradel KO, de Muckadell OB, Kjeldsen J. Pre-operative use of anti-TNF-α agents and the risk of post-operative complications in patients with Crohn’s disease—a nationwide cohort study. Aliment Pharmacol Ther. 2013;37(2):214–24.CrossRefPubMed
18.
go back to reference Syed A, Cross RK, Flasar MH. Anti-tumor necrosis factor therapy is associated with infections after abdominal surgery in Crohn’s disease patients. Am J Gastroenterol. 2013;108(4):583–93CrossRefPubMed Syed A, Cross RK, Flasar MH. Anti-tumor necrosis factor therapy is associated with infections after abdominal surgery in Crohn’s disease patients. Am J Gastroenterol. 2013;108(4):583–93CrossRefPubMed
19.
go back to reference Strong S, Steele SR, Boutrous M, Bordineau L, Chun J, Stewart DB, Vogel J, Rafferty JF; Clinical Practice Guidelines Committee of the American Society of Colon and Rectal Surgeons. Clinical Practice Guideline for the Surgical Management of Crohn’s Disease. Dis Colon Rectum. 2015;58(11):1021–36.CrossRefPubMed Strong S, Steele SR, Boutrous M, Bordineau L, Chun J, Stewart DB, Vogel J, Rafferty JF; Clinical Practice Guidelines Committee of the American Society of Colon and Rectal Surgeons. Clinical Practice Guideline for the Surgical Management of Crohn’s Disease. Dis Colon Rectum. 2015;58(11):1021–36.CrossRefPubMed
20.
go back to reference Shaukat A, Virnig DJ, Howard D, Sitaraman SV, Liff JM, Lederle FA. Crohn’s disease and small bowel adenocarcinoma: A population-based case–control study. Cancer Epidemiol Biomarkers Prev. 2011;20(6):1120–1123.CrossRefPubMed Shaukat A, Virnig DJ, Howard D, Sitaraman SV, Liff JM, Lederle FA. Crohn’s disease and small bowel adenocarcinoma: A population-based case–control study. Cancer Epidemiol Biomarkers Prev. 2011;20(6):1120–1123.CrossRefPubMed
21.
go back to reference Collier PE, Turowski P, Diamond DL. Small intestinal adenocarcinoma complicating regional enteritis. Cancer. 1985;55(3):516–521.CrossRefPubMed Collier PE, Turowski P, Diamond DL. Small intestinal adenocarcinoma complicating regional enteritis. Cancer. 1985;55(3):516–521.CrossRefPubMed
22.
go back to reference Dossett LA, White LM, Welch DC, Herline AJ, Muldoon RL, Schwartz DA, Wise PE. Small bowel adenocarcinoma complicating Crohn’s disease: case series and review of the literature. Am Surg. 2007;73(11):1181–7.PubMed Dossett LA, White LM, Welch DC, Herline AJ, Muldoon RL, Schwartz DA, Wise PE. Small bowel adenocarcinoma complicating Crohn’s disease: case series and review of the literature. Am Surg. 2007;73(11):1181–7.PubMed
23.
go back to reference Fazio VW, Marchetti F, Church M, et al. Effect of resection margins on the recurrence of Crohn’s disease in the small bowel. A randomized controlled trial. Ann Surg. 1996;224(4):563–71; discussion 571–3.CrossRefPubMedPubMedCentral Fazio VW, Marchetti F, Church M, et al. Effect of resection margins on the recurrence of Crohn’s disease in the small bowel. A randomized controlled trial. Ann Surg. 1996;224(4):563–71; discussion 571–3.CrossRefPubMedPubMedCentral
24.
go back to reference He X, Chen Z, Huang J, et al. Stapled side-to-side anastomosis might be better than handsewn end-to-end anastomosis in ileocolic resection for Crohn’s disease: A meta-analysis. Dig Dis Sci. 2014;59(7):1544–1551.CrossRefPubMed He X, Chen Z, Huang J, et al. Stapled side-to-side anastomosis might be better than handsewn end-to-end anastomosis in ileocolic resection for Crohn’s disease: A meta-analysis. Dig Dis Sci. 2014;59(7):1544–1551.CrossRefPubMed
25.
go back to reference McLeod RS, Wolff BG, Ross S, Parkes R, McKenzie M, Investigators of the CAST Trial. Recurrence of Crohn’s disease after ileocolic resection is not affected by anastomotic type: Results of a multicenter, randomized, controlled trial. Dis Colon Rectum. 2009;52(5):919–927.CrossRefPubMed McLeod RS, Wolff BG, Ross S, Parkes R, McKenzie M, Investigators of the CAST Trial. Recurrence of Crohn’s disease after ileocolic resection is not affected by anastomotic type: Results of a multicenter, randomized, controlled trial. Dis Colon Rectum. 2009;52(5):919–927.CrossRefPubMed
26.
go back to reference Ikeuchi H, Kusunoki M, Yamamura T. Long-term results of stapled and hand-sewn anastomoses in patients with Crohn’s disease. Dig Surg. 2000;17(5):493–496.CrossRefPubMed Ikeuchi H, Kusunoki M, Yamamura T. Long-term results of stapled and hand-sewn anastomoses in patients with Crohn’s disease. Dig Surg. 2000;17(5):493–496.CrossRefPubMed
27.
go back to reference Zurbuchen U, Kroesen AJ, Knebel P, et al. Complications after end-to-end vs. side-to-side anastomosis in ileocecal Crohn’s disease—early postoperative results from a randomized controlled multi-center trial (ISRCTN-45665492). Langenbeck’s Archives of Surgery. 2013;398(3):467–474.CrossRefPubMed Zurbuchen U, Kroesen AJ, Knebel P, et al. Complications after end-to-end vs. side-to-side anastomosis in ileocecal Crohn’s disease—early postoperative results from a randomized controlled multi-center trial (ISRCTN-45665492). Langenbeck’s Archives of Surgery. 2013;398(3):467–474.CrossRefPubMed
28.
go back to reference Bakkevold KE. Construction of an ileocolic neosphincter—Nipple valve anastomosis for prevention of postoperative recurrence of Crohn’s disease in the neoterminal ileum after ileocecal or ileocolic resection: A long-term follow-up study. Journal of Crohn’s and Colitis. 2009;3(3):183–188.CrossRefPubMed Bakkevold KE. Construction of an ileocolic neosphincter—Nipple valve anastomosis for prevention of postoperative recurrence of Crohn’s disease in the neoterminal ileum after ileocecal or ileocolic resection: A long-term follow-up study. Journal of Crohn’s and Colitis. 2009;3(3):183–188.CrossRefPubMed
29.
go back to reference D’Haens GR, Geboes K, Peeters M, Baert F, Penninckx F, Rutgeerts P. Early lesions of recurrent Crohn’s disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology. 1998;114(2):262–267.CrossRefPubMed D’Haens GR, Geboes K, Peeters M, Baert F, Penninckx F, Rutgeerts P. Early lesions of recurrent Crohn’s disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology. 1998;114(2):262–267.CrossRefPubMed
30.
go back to reference Kono T, Ashida T, Ebisawa Y, et al. A new antimesenteric functional end-to-end handsewn anastomosis: Surgical prevention of anastomotic recurrence in Crohn’s disease. Dis Colon Rectum. 2011;54(5):586–592.CrossRefPubMed Kono T, Ashida T, Ebisawa Y, et al. A new antimesenteric functional end-to-end handsewn anastomosis: Surgical prevention of anastomotic recurrence in Crohn’s disease. Dis Colon Rectum. 2011;54(5):586–592.CrossRefPubMed
31.
go back to reference Rutgeerts P, Peeters M, Hiele M, et al. Effect of faecal stream diversion on recurrence of Crohn’s disease in the neoterminal ileum. The Lancet. 1991;338(8770):771–774.CrossRef Rutgeerts P, Peeters M, Hiele M, et al. Effect of faecal stream diversion on recurrence of Crohn’s disease in the neoterminal ileum. The Lancet. 1991;338(8770):771–774.CrossRef
32.
go back to reference Milson JW, Hammerhofer KA, Böhm B, Marcello P, Elson P, Fazio VW. Prospective, randomized trial comparing laparoscopic vs. conventional surgery for refractory ileocolic Crohn’s disease. Diseases of the colon & rectum. 2001;44(1):1–8.CrossRef Milson JW, Hammerhofer KA, Böhm B, Marcello P, Elson P, Fazio VW. Prospective, randomized trial comparing laparoscopic vs. conventional surgery for refractory ileocolic Crohn’s disease. Diseases of the colon & rectum. 2001;44(1):1–8.CrossRef
33.
go back to reference Maartense S, Dunker MS, Slors JF, et al. Laparoscopic-assisted versus open ileocolic resection for Crohn’s disease: A randomized trial. Ann Surg. 2006;243(2):143–9; discussion 150–3.CrossRefPubMedPubMedCentral Maartense S, Dunker MS, Slors JF, et al. Laparoscopic-assisted versus open ileocolic resection for Crohn’s disease: A randomized trial. Ann Surg. 2006;243(2):143–9; discussion 150–3.CrossRefPubMedPubMedCentral
34.
go back to reference Eshuis EJ, Slors JFM, Stokkers PC, et al. Long‐term outcomes following laparoscopically assisted versus open ileocolic resection for Crohn’s disease. Br J Surg. 2010;97(4):563–568.CrossRefPubMed Eshuis EJ, Slors JFM, Stokkers PC, et al. Long‐term outcomes following laparoscopically assisted versus open ileocolic resection for Crohn’s disease. Br J Surg. 2010;97(4):563–568.CrossRefPubMed
35.
go back to reference Stocchi L, Milsom JW, Fazio VW. Long-term outcomes of laparoscopic versus open ileocolic resection for Crohn’s disease: Follow-up of a prospective randomized trial. Surgery. 2008;144(4):622–628.CrossRefPubMed Stocchi L, Milsom JW, Fazio VW. Long-term outcomes of laparoscopic versus open ileocolic resection for Crohn’s disease: Follow-up of a prospective randomized trial. Surgery. 2008;144(4):622–628.CrossRefPubMed
36.
go back to reference Heaton LD, Ravdin IS, Blades B, Whelan TJ. President Eisenhower’s operation for regional enteritis: A footnote to history. Ann Surg. 1964;159:661–666.CrossRefPubMedPubMedCentral Heaton LD, Ravdin IS, Blades B, Whelan TJ. President Eisenhower’s operation for regional enteritis: A footnote to history. Ann Surg. 1964;159:661–666.CrossRefPubMedPubMedCentral
37.
go back to reference Michelassi F, Upadhyay GA. Side-to-side isoperistaltic strictureplasty in the treatment of extensive Crohn’s disease. J Surg Res. 2004;117(1):71–78.CrossRefPubMed Michelassi F, Upadhyay GA. Side-to-side isoperistaltic strictureplasty in the treatment of extensive Crohn’s disease. J Surg Res. 2004;117(1):71–78.CrossRefPubMed
38.
go back to reference Yamamoto T, Fazio VW, Tekkis PP. Safety and efficacy of strictureplasty for Crohn’s disease: A systematic review and meta-analysis. Diseases of the colon & rectum. 2007;50(11):1968–1986.CrossRef Yamamoto T, Fazio VW, Tekkis PP. Safety and efficacy of strictureplasty for Crohn’s disease: A systematic review and meta-analysis. Diseases of the colon & rectum. 2007;50(11):1968–1986.CrossRef
39.
go back to reference Campbell L, Ambe R, Weaver J, Marcus SM, Cagir B. Comparison of conventional and nonconventional strictureplasties in Crohn’s disease: A systematic review and meta-analysis. Dis Colon Rectum. 2012;55(6):714–726.CrossRefPubMed Campbell L, Ambe R, Weaver J, Marcus SM, Cagir B. Comparison of conventional and nonconventional strictureplasties in Crohn’s disease: A systematic review and meta-analysis. Dis Colon Rectum. 2012;55(6):714–726.CrossRefPubMed
40.
go back to reference Yamamoto T, Bain IM, Allan RN, Keighley MR. An audit of strictureplasty for small-bowel Crohn’s disease. Dis Colon Rectum. 1999;42(6):797–803.CrossRefPubMed Yamamoto T, Bain IM, Allan RN, Keighley MR. An audit of strictureplasty for small-bowel Crohn’s disease. Dis Colon Rectum. 1999;42(6):797–803.CrossRefPubMed
41.
go back to reference Hassan C, Zullo A, De Francesco V, et al. Systematic review: Endoscopic dilatation in Crohn’s disease. Aliment Pharmacol Ther. 2007;26(11–12):1457–1464.CrossRefPubMed Hassan C, Zullo A, De Francesco V, et al. Systematic review: Endoscopic dilatation in Crohn’s disease. Aliment Pharmacol Ther. 2007;26(11–12):1457–1464.CrossRefPubMed
42.
go back to reference Hirai F, Beppu T, Takatsu N, et al. Long‐term outcome of endoscopic balloon dilation for small bowel strictures in patients with Crohn’s disease. Digestive Endoscopy. 2014;26(4):545–551.CrossRefPubMed Hirai F, Beppu T, Takatsu N, et al. Long‐term outcome of endoscopic balloon dilation for small bowel strictures in patients with Crohn’s disease. Digestive Endoscopy. 2014;26(4):545–551.CrossRefPubMed
43.
go back to reference Wibmer AG, Kroesen AJ, Gröne J, Buhr H, Ritz J. Comparison of strictureplasty and endoscopic balloon dilatation for stricturing Crohn’s disease—review of the literature. Int J Colorectal Dis. 2010;25(10):1149–1157.CrossRefPubMed Wibmer AG, Kroesen AJ, Gröne J, Buhr H, Ritz J. Comparison of strictureplasty and endoscopic balloon dilatation for stricturing Crohn’s disease—review of the literature. Int J Colorectal Dis. 2010;25(10):1149–1157.CrossRefPubMed
44.
go back to reference Hendel J, Karstensen JG, Vilmann P. Serial intralesional injections of infliximab in small bowel Crohn’s strictures are feasible and might lower inflammation. United European Gastroenterol J. 2014;2(5):406–12.CrossRefPubMedPubMedCentral Hendel J, Karstensen JG, Vilmann P. Serial intralesional injections of infliximab in small bowel Crohn’s strictures are feasible and might lower inflammation. United European Gastroenterol J. 2014;2(5):406–12.CrossRefPubMedPubMedCentral
45.
go back to reference Di Nardo G, Oliva S, Passariello M, Pallotta N, Civitelli F, Frediani S, Gualdi G, Gandullia P, Mallardo S, Cucchiara S. Intralesional steroid injection after endoscopic balloon dilation in pediatric Crohn’s disease with stricture: a prospective, randomized, double-blind, controlled trial. Gastrointest Endosc. 2010;72(6):1201–8.CrossRefPubMed Di Nardo G, Oliva S, Passariello M, Pallotta N, Civitelli F, Frediani S, Gualdi G, Gandullia P, Mallardo S, Cucchiara S. Intralesional steroid injection after endoscopic balloon dilation in pediatric Crohn’s disease with stricture: a prospective, randomized, double-blind, controlled trial. Gastrointest Endosc. 2010;72(6):1201–8.CrossRefPubMed
46.
go back to reference Attar A, Maunoury V, Vahedi K, et al. Safety and efficacy of extractible self‐expandable metal stents in the treatment of Crohn’s disease intestinal strictures: A prospective pilot study. Inflamm Bowel Dis. 2012;18(10):1849–1854.CrossRefPubMed Attar A, Maunoury V, Vahedi K, et al. Safety and efficacy of extractible self‐expandable metal stents in the treatment of Crohn’s disease intestinal strictures: A prospective pilot study. Inflamm Bowel Dis. 2012;18(10):1849–1854.CrossRefPubMed
47.
go back to reference Wright EK, Kamm MA, De Cruz P, et al. Measurement of fecal calprotectin improves monitoring and detection of recurrence of Crohn’s disease after surgery. Gastroenterology. 2015;148(5):938–947. e1.CrossRefPubMed Wright EK, Kamm MA, De Cruz P, et al. Measurement of fecal calprotectin improves monitoring and detection of recurrence of Crohn’s disease after surgery. Gastroenterology. 2015;148(5):938–947. e1.CrossRefPubMed
48.
go back to reference Best WR, Becktel JM, Singleton JW, Kern F. Development of a Crohn’s disease activity index. Gastroenterology. 1976;70(3):439–444.PubMed Best WR, Becktel JM, Singleton JW, Kern F. Development of a Crohn’s disease activity index. Gastroenterology. 1976;70(3):439–444.PubMed
49.
go back to reference Regueiro M, Kip KE, Schraut W, et al. Crohn’s disease activity index does not correlate with endoscopic recurrence one year after ileocolonic resection. Inflamm Bowel Dis. 2011;17(1):118–126.CrossRefPubMed Regueiro M, Kip KE, Schraut W, et al. Crohn’s disease activity index does not correlate with endoscopic recurrence one year after ileocolonic resection. Inflamm Bowel Dis. 2011;17(1):118–126.CrossRefPubMed
50.
go back to reference Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M. Predictability of the postoperative course of Crohn’s disease. Gastroenterology. 1990;99(4):956–963.CrossRefPubMed Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M. Predictability of the postoperative course of Crohn’s disease. Gastroenterology. 1990;99(4):956–963.CrossRefPubMed
51.
go back to reference Brignola C, Cottone M, Pera A, Ardizzone S, Scribano ML, De Franchis R, D’Arienzo A, D’Albasio G, Pennestri D. Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn’s disease. Italian Cooperative Study Group. Gastroenterology. 1995;108(2):345–9. Brignola C, Cottone M, Pera A, Ardizzone S, Scribano ML, De Franchis R, D’Arienzo A, D’Albasio G, Pennestri D. Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn’s disease. Italian Cooperative Study Group. Gastroenterology. 1995;108(2):345–9.
52.
go back to reference Florent C, Cortot A, Quandale P, Sahmound T, Modigliani R, Sarfaty E, Valleur P, Dupas JL, Daurat M, Faucheron JL, Lerebours E, Michot F, Belaiche J, Jacquet N, Soulé JC, Rothman N, Gendre JP, Malafosse M. Placebo-controlled clinical trial of mesalazine in the prevention of early endoscopic recurrences after resection for Crohn’s disease. Groupe d’Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID). Eur J Gastroenterol Hepatol. 1996;8(3):229–33.CrossRefPubMed Florent C, Cortot A, Quandale P, Sahmound T, Modigliani R, Sarfaty E, Valleur P, Dupas JL, Daurat M, Faucheron JL, Lerebours E, Michot F, Belaiche J, Jacquet N, Soulé JC, Rothman N, Gendre JP, Malafosse M. Placebo-controlled clinical trial of mesalazine in the prevention of early endoscopic recurrences after resection for Crohn’s disease. Groupe d’Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID). Eur J Gastroenterol Hepatol. 1996;8(3):229–33.CrossRefPubMed
53.
go back to reference Lochs H, Mayer M, Fleig WE, Mortensen PB, Bauer P, Genser D, Petritsch W, Raithel M, Hoffmann R, Gross V, Plauth M, Staun M, Nesje LB. Prophylaxis of postoperative relapse in Crohn’s disease with mesalamine: European Cooperative Crohn’s Disease Study VI. Gastroenterology. 2000;118(2):264–73.CrossRefPubMed Lochs H, Mayer M, Fleig WE, Mortensen PB, Bauer P, Genser D, Petritsch W, Raithel M, Hoffmann R, Gross V, Plauth M, Staun M, Nesje LB. Prophylaxis of postoperative relapse in Crohn’s disease with mesalamine: European Cooperative Crohn’s Disease Study VI. Gastroenterology. 2000;118(2):264–73.CrossRefPubMed
54.
go back to reference McLeod RS, Wolff BG, Steinhart AH, Carryer PW, O’Rourke K, Andrews DF, Blair JE, Cangemi JR, Cohen Z, Cullen JB, et al. Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn’s disease. Gastroenterology. 1995;109(2):404–13.CrossRefPubMed McLeod RS, Wolff BG, Steinhart AH, Carryer PW, O’Rourke K, Andrews DF, Blair JE, Cangemi JR, Cohen Z, Cullen JB, et al. Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn’s disease. Gastroenterology. 1995;109(2):404–13.CrossRefPubMed
55.
go back to reference Rutgeerts P, Hiele M, Geboes K, et al. Controlled trial of metronidazole treatment for prevention of Crohn’s recurrence after ileal resection. Gastroenterology. 1995;108(6):1617–1621.CrossRefPubMed Rutgeerts P, Hiele M, Geboes K, et al. Controlled trial of metronidazole treatment for prevention of Crohn’s recurrence after ileal resection. Gastroenterology. 1995;108(6):1617–1621.CrossRefPubMed
56.
go back to reference Rutgeerts P, Van Assche G, Vermeire S, et al. Ornidazole for prophylaxis of postoperative Crohn’s disease recurrence: A randomized, double-blind, placebo-controlled trial. Gastroenterology. 2005;128(4):856–861.CrossRefPubMed Rutgeerts P, Van Assche G, Vermeire S, et al. Ornidazole for prophylaxis of postoperative Crohn’s disease recurrence: A randomized, double-blind, placebo-controlled trial. Gastroenterology. 2005;128(4):856–861.CrossRefPubMed
57.
go back to reference Ardizzone S, Maconi G, Sampietro GM, et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn’s disease. Gastroenterology. 2004;127(3):730–740.CrossRefPubMed Ardizzone S, Maconi G, Sampietro GM, et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn’s disease. Gastroenterology. 2004;127(3):730–740.CrossRefPubMed
58.
go back to reference D’Haens GR, Vermeire S, Van Assche G, et al. Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn’s disease: A controlled randomized trial. Gastroenterology. 2008;135(4):1123–1129.CrossRefPubMed D’Haens GR, Vermeire S, Van Assche G, et al. Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn’s disease: A controlled randomized trial. Gastroenterology. 2008;135(4):1123–1129.CrossRefPubMed
59.
go back to reference Hanauer SB, Korelitz BI, Rutgeerts P, et al. Postoperative maintenance of Crohn’s disease remission with 6-mercaptopurine, mesalamine, or placebo: A 2-year trial. Gastroenterology. 2004;127(3):723–729.CrossRefPubMed Hanauer SB, Korelitz BI, Rutgeerts P, et al. Postoperative maintenance of Crohn’s disease remission with 6-mercaptopurine, mesalamine, or placebo: A 2-year trial. Gastroenterology. 2004;127(3):723–729.CrossRefPubMed
60.
go back to reference Nos P, Hinojosa J, Aguilera V, Molés JR, Pastor M, Ponce J, Berenguer J. Azathioprine and 5-ASA in the prevention of postoperative recurrence of Crohn’s disease. Gastroenterol Hepatol. 2000;23(8):374–8.PubMed Nos P, Hinojosa J, Aguilera V, Molés JR, Pastor M, Ponce J, Berenguer J. Azathioprine and 5-ASA in the prevention of postoperative recurrence of Crohn’s disease. Gastroenterol Hepatol. 2000;23(8):374–8.PubMed
61.
go back to reference Reinisch W, Angelberger S, Petritsch W, et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn’s disease with endoscopic recurrence: Efficacy and safety results of a randomised, double-blind, double-dummy, multicentre trial. Gut. 2010;59(6):752–759.CrossRefPubMed Reinisch W, Angelberger S, Petritsch W, et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn’s disease with endoscopic recurrence: Efficacy and safety results of a randomised, double-blind, double-dummy, multicentre trial. Gut. 2010;59(6):752–759.CrossRefPubMed
62.
go back to reference Armuzzi A, Felice C, Papa A, et al. Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn’s disease: An open-label pilot study. J Crohns Colitis. 2013;7(12):e623-9.CrossRefPubMed Armuzzi A, Felice C, Papa A, et al. Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn’s disease: An open-label pilot study. J Crohns Colitis. 2013;7(12):e623-9.CrossRefPubMed
63.
go back to reference Regueiro M, Schraut W, Baidoo L, et al. Infliximab prevents Crohn’s disease recurrence after ileal resection. Gastroenterology. 2009;136(2):441–450. e1.CrossRefPubMed Regueiro M, Schraut W, Baidoo L, et al. Infliximab prevents Crohn’s disease recurrence after ileal resection. Gastroenterology. 2009;136(2):441–450. e1.CrossRefPubMed
64.
go back to reference Savarino E, Bodini G, Dulbecco P, et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn’s disease: A randomized controlled trial. Am J Gastroenterol. 2013;108(11):1731–1742.CrossRefPubMed Savarino E, Bodini G, Dulbecco P, et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn’s disease: A randomized controlled trial. Am J Gastroenterol. 2013;108(11):1731–1742.CrossRefPubMed
65.
go back to reference Yoshida K, Fukunaga K, Ikeuchi H, et al. Scheduled infliximab monotherapy to prevent recurrence of Crohn’s disease following ileocolic or ileal resection: A 3‐year prospective randomized open trial. Inflamm Bowel Dis. 2012;18(9):1617–1623.CrossRefPubMed Yoshida K, Fukunaga K, Ikeuchi H, et al. Scheduled infliximab monotherapy to prevent recurrence of Crohn’s disease following ileocolic or ileal resection: A 3‐year prospective randomized open trial. Inflamm Bowel Dis. 2012;18(9):1617–1623.CrossRefPubMed
66.
go back to reference Doherty G, Bennett G, Patil S, Cheifetz A, Moss AC. Interventions for prevention of post‐operative recurrence of Crohn’s disease. The Cochrane Library. 2009. Doherty G, Bennett G, Patil S, Cheifetz A, Moss AC. Interventions for prevention of post‐operative recurrence of Crohn’s disease. The Cochrane Library. 2009.
67.
go back to reference Jones G, Kennedy N, Lees C, Arnott I, Satsangi J. Systematic review: The use of thiopurines or anti‐TNF in post‐operative Crohn’s disease maintenance—progress and prospects. Aliment Pharmacol Ther. 2014;39(11):1253–1265.CrossRefPubMed Jones G, Kennedy N, Lees C, Arnott I, Satsangi J. Systematic review: The use of thiopurines or anti‐TNF in post‐operative Crohn’s disease maintenance—progress and prospects. Aliment Pharmacol Ther. 2014;39(11):1253–1265.CrossRefPubMed
68.
go back to reference Herfarth H, Tjaden C, Lukas M, et al. Adverse events in clinical trials with azathioprine and mesalamine for prevention of postoperative recurrence of Crohn’s disease. Gut. 2006;55(10):1525–1526.PubMedPubMedCentral Herfarth H, Tjaden C, Lukas M, et al. Adverse events in clinical trials with azathioprine and mesalamine for prevention of postoperative recurrence of Crohn’s disease. Gut. 2006;55(10):1525–1526.PubMedPubMedCentral
69.
go back to reference Regueiro M, Kip KE, Baidoo L, Swoger JM, Schraut W. Postoperative therapy with infliximab prevents long-term Crohn’s disease recurrence. Clinical Gastroenterology and Hepatology. 2014;12(9):1494–1502e1.CrossRefPubMed Regueiro M, Kip KE, Baidoo L, Swoger JM, Schraut W. Postoperative therapy with infliximab prevents long-term Crohn’s disease recurrence. Clinical Gastroenterology and Hepatology. 2014;12(9):1494–1502e1.CrossRefPubMed
70.
go back to reference D’Haens G, Baert F, Van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: An open randomised trial. The Lancet. 2008;371(9613):660–667.CrossRef D’Haens G, Baert F, Van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: An open randomised trial. The Lancet. 2008;371(9613):660–667.CrossRef
71.
go back to reference Schreiber S, Colombel J, Bloomfield R, et al. Increased response and remission rates in short-duration Crohn’s disease with subcutaneous certolizumab pegol: An analysis of PRECiSE 2 randomized maintenance trial data. Am J Gastroenterol. 2010;105(7):1574–1582.CrossRefPubMed Schreiber S, Colombel J, Bloomfield R, et al. Increased response and remission rates in short-duration Crohn’s disease with subcutaneous certolizumab pegol: An analysis of PRECiSE 2 randomized maintenance trial data. Am J Gastroenterol. 2010;105(7):1574–1582.CrossRefPubMed
72.
go back to reference Bordeianou L, Stein SL, Ho VP, et al. Immediate versus tailored prophylaxis to prevent symptomatic recurrences after surgery for ileocecal Crohn’s disease? Surgery. 2011;149(1):72–78.CrossRefPubMed Bordeianou L, Stein SL, Ho VP, et al. Immediate versus tailored prophylaxis to prevent symptomatic recurrences after surgery for ileocecal Crohn’s disease? Surgery. 2011;149(1):72–78.CrossRefPubMed
73.
go back to reference De Cruz P, Kamm MA, Hamilton AL, et al. Crohn’s disease management after intestinal resection: A randomised trial. The Lancet. 2015;385(9976):1406–1417.CrossRef De Cruz P, Kamm MA, Hamilton AL, et al. Crohn’s disease management after intestinal resection: A randomised trial. The Lancet. 2015;385(9976):1406–1417.CrossRef
74.
go back to reference VanDussen KL, Marinshaw JM, Shaikh N, Miyoshi H, Moon C, Tarr PI, Ciorba MA, Stappenbeck TS. Development of an enhanced human gastrointestinal epithelial culture system to facilitate patient-based assays. Gut. 2015;64(6):911–20.CrossRefPubMed VanDussen KL, Marinshaw JM, Shaikh N, Miyoshi H, Moon C, Tarr PI, Ciorba MA, Stappenbeck TS. Development of an enhanced human gastrointestinal epithelial culture system to facilitate patient-based assays. Gut. 2015;64(6):911–20.CrossRefPubMed
Metadata
Title
Surgical Considerations in the Treatment of Small Bowel Crohn’s Disease
Authors
Lillias Holmes Maguire
Karim Alavi
Ranjan Sudan
Paul E. Wise
Andreas M. Kaiser
Liliana Bordeianou
Publication date
01-02-2017
Publisher
Springer US
Published in
Journal of Gastrointestinal Surgery / Issue 2/2017
Print ISSN: 1091-255X
Electronic ISSN: 1873-4626
DOI
https://doi.org/10.1007/s11605-016-3330-9

Other articles of this Issue 2/2017

Journal of Gastrointestinal Surgery 2/2017 Go to the issue